Purchase this article with an account.
John Alexander Gonzales, Jaskirat Takhar, Vatinee Y Bunya, Jennifer Rose-Nussbaumer, Annie Chou, Lindsey Criswell, Caroline Shiboski, Tom Lietman; Overall and Cancer-Related Mortality in the Sjögren’s International Collaborative Clinical Alliance (SICCA). Invest. Ophthalmol. Vis. Sci. 2019;60(9):6506.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
While Sjögren’s syndrome (SS) is known to be associated with an increased incidence of lymphoproliferative disorders, little is known about how SS adversely affects survival. Our objective was to describe all-cause and cancer-related mortality in participants enrolled into the UCSF cohort of the Sjögren’s International Collaborative Clinical Alliance (SICCA).
Retrospective review of the SICCA database registry. Patients were classified as SS or non-SS based on the recently updated American College of Rheumatology/EUropean Leaugue Against Rheumatism (ACR/EULAR) criteria. Demographic information was obtained from the SICCA registry while mortality information was obtained from the United States National Death Index. Descriptive statistics were used to examine relationships between cancer-related death, female gender, and age. Logistic regression was performed to identify an association between SS cancer-related mortality.
A total of 718 subjects were enrolled into the UCSF SICCA registry cohort. By December 31, 2017, 29 participants had died. There were 13 (53.9% female) participants who died classified as non-SS (mean age 70 years, range 54.6 to 87.8 years) and 12 participants (100% female) who died classified as SS (mean age 71.9 years, range 45.0 to 91.0 years). Four participants were unable to be classified according to ACR/EULAR criteria. In deceased participants classified as SS, cancer was the cause of death in 58.3% while in non-SS deceased participants, cancer was the cause of death in 44.4%. Four participants died to lymphoma-related cancer with 3 being classified as SS and one that was unable to be classified. There was no statistically significant association between being classified as SS and dying from cancer (p=0.22).
A higher proportion of women with SS died from cancer-related causes, though we did not find that being classified as SS conferred a higher odds of dying from cancer. Because SS predominantly affects women, it is important to be aware of its impact on women’s mortality.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only